Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3052W HIGH $5.43
Volume
119.13 K
Value Traded
6.02 M
Short % Float
6.01%
+3.8%Week
+16.04%1 Month
+112.07%3 Month
+225.83%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
720.51 M
EPS (TTM)
-0.30
P/E Ratio
-
Ent. Value
661.27 M
Total Shares
144.92 M
Float Shares
118.51 M
Insiders
18.49%
Institutions
49.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OABI Catalyst Timeline
Dated clinical, regulatory and corporate events for OmniAb, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for OmniAb, Inc. Common Stock
230Total events
7Upcoming
82Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
OmniAb announces global collaboration and license agreement with Eli Lilly for ion channel program
●Quarterly UpdateCorporate
OmniAb reports second quarter 2026 financial results and business highlights
◆Topline ReadoutbatoclimabFiledClinical Data
Topline data announced from two Phase 3 studies of batoclimab in thyroid eye disease
thyroid eye diseasesource ↗
▲Oral Presentationprecemtabart tocentecanPresentation
Pooled data from PROCEADE-CRC-01 presented at ASCO GI
metastatic colorectal cancersource ↗
▲RWE DataSUBLOCADEClinical Data
Announced findings from two real-world evidence studies
opioid use disordersource ↗
▲Quarterly UpdateSUBLOCADECorporate
Record quarterly SUBLOCADE net revenue of $253M in Q2'26
opioid use disordersource ↗
◆Oral PresentationPresentation
Jefferies Global Healthcare Conference corporate overview presentation
◆Oral PresentationPresentation
Multiple partner programs to be highlighted at ASCO Annual Meeting
◆Oral PresentationPresentation
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference meetings
◆Quarterly UpdateCorporate
OmniAb to report first quarter 2026 financial results and hold conference call
◆Oral PresentationPresentation
H.C. Wainwright 2nd Annual Royalty Company Virtual Conference fireside chat
▲Topline ReadoutIMVT-1402Clinical Data
Immunovant announced preliminary week 16 IMVT-1402 results in difficult-to-treat rheumatoid arthritis
rheumatoid arthritissource ↗
▲Topline ReadoutTEV-'408Clinical Data
Topline results in Phase 1b trial of TEV-'408 for vitiligo showed improvements in skin pigmentation
vitiligosource ↗
◆Trial Initiationprecemtabart tocentecanTrial
Phase 3 trial initiation anticipated for precemtabart tocentecan
metastatic colorectal cancersource ↗
▲Partnership / LicenseCorporate
OmniAb enters new license agreements with EnRosa Therapeutics and argenx
▲Trial InitiationRamantamigTrial
Ramantamig (JNJ-79635322) advanced to Phase 3 from Phase 1
relapsed or refractory multiple myelomasource ↗
▲First Patient Dosedprecemtabart tocentecanTrial
First patient dosed in Phase 3 PROCEADE-CRC-03 trial of precemtabart tocentecan
metastatic colorectal cancersource ↗
▲PK PD Dataprecemtabart tocentecanClinical Data
Phase 1 data from PROCEADE-CRC-01 showed predictable and manageable safety
metastatic colorectal cancersource ↗
▲Partnership / LicenseTEV-'408Corporate
Teva and Royalty Pharma enter funding agreement of up to $500 million for TEV-'408
vitiligosource ↗
●Trial InitiationTrial
Boehringer Ingelheim commenced Phase 2a study of BI 3802876 in MASH cirrhosis
compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)source ↗
▲Partnership / LicensesugemalimabFiledCorporate
Arrotex Pharmaceuticals enters exclusive commercialization agreement with CStone for Sugemalimab in Australia and New Zealand
non-small cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, extranodal NK/T-cell lymphomasource ↗
▲Preclinical PoCVXA-222Preclinical
VERAXA Biotech announced advancement of bispecific ADC program VXA-222 following key technical milestone
solid tumorssource ↗
●Trial InitiationIMVT-1402Trial
Initiate clinical trials in total of 10 indications by March 31, 2026
multiple indicationssource ↗
▲Enrollment CompleteIMVT-1402Trial
IMVT-1402 registrational trial in rheumatoid arthritis fully enrolled
rheumatoid arthritissource ↗
▼Program DiscontinuationCorporate
Discontinuation of legacy small-molecule ion channel programs
◆Topline ReadoutTEV-'408Clinical Data
Topline results expected for TEV-'408 in vitiligo
vitiligosource ↗
▲Oral Presentationprecemtabart tocentecanPresentation
Pooled data presented at ASCO GI on precemtabart tocentecan
metastatic colorectal cancersource ↗
▲Enrollment CompleteIMVT-1402Trial
IMVT-1402 registrational trial in rheumatoid arthritis fully enrolled
rheumatoid arthritissource ↗
▲Runway Guidance UpdateCorporate
OmniAb raises full year 2026 cash and cash equivalents guidance to $49-53 million
▲Platform ValidationOmniUltraPreclinical
OmniAb launches OmniUltra transgenic chicken platform
●Trial InitiationRNDO-564Trial
Initiate Phase 1b trial in relapsed/refractory locally advanced metastatic bladder cancer by year-end 2025
advanced bladder cancersource ↗
●Poster PresentationRNDO-564Presentation
Abstract accepted for SITC 2025 presentation on November 7
Solid tumorssource ↗
▲Partnership / LicenseCorporate
OmniAb enters into new license agreements with Dana Farber Cancer Institute, Mabtrx Biosciences, and two global pharmaceutical companies
●PublicationPresentation
OmniAb and GSK publish paper on Nav1.1 sodium channel potentiator in Molecular Pharmacology
seizure disorderssource ↗
◆Oral PresentationmipletamigPresentation
Present results at ASH meeting in Q4 2025
acute myeloid leukemiasource ↗
▲Oral PresentationbatoclimabFiledPresentation
Abstract presented at ATA 2025 with six-month off-treatment data in GD
Graves' diseasesource ↗
◆Topline ReadoutbatoclimabFiledClinical Data
Top-line results from pivotal program of batoclimab for TED expected in H2 2025
thyroid eye diseasesource ↗
◆Oral PresentationdomvanalimabPresentation
Present OS data from Phase 2 EDGE-Gastric study in fall 2025
upper gastrointestinal adenocarcinomassource ↗
Past FDA Catalysts and PDUFA Decisions
How OABI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
OmniAb, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every OABI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bertozzi Carolyn RDirector | Option | 20,000 113,308 held | $0.00 | 06/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OABI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 480.00 K | 300.00 K |
OABI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OABI ranks across every disease it competes in
Competitive Position is a premium feature
See how OABI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOABI News
-OABI
Oct 6, 2026▼ -0.2%today
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
OmniAb, Inc. hosted its Investor & Analyst Day in Emeryville, CA, showcasing significant advancements in its partner pipeline and technology platforms. The event featured the introduction of the OmniTides™ peptide discovery platform and updates on the xPloration® platform. These developments indicate OmniAb's commitment to enhancing its therapeutic discovery capabilities.
Read more →-OABI
Sep 14, 2026▲ +10.1%on this news
OmniAb to Host Investor & Analyst Day on October 6, 2026
OmniAb, Inc. has announced its Investor & Analyst Day scheduled for October 6, 2026, in Emeryville, CA. The event will include presentations from the company's executive leadership team, covering corporate updates and technology innovations. Attendees can expect insights into select partner programs and a Q&A session.
Read more →-OABI
Aug 26, 2026OmniAb to Participate in Upcoming Investor Conferences
OmniAb, Inc. has announced its participation in two upcoming investor conferences, the Nasdaq/LD Micro Summit and the H.C. Wainwright 28th Annual Global Investment Conference. These events are scheduled for September 9 and September 15, 2026, respectively. The company's involvement in these conferences underscores its commitment to engaging with the investment community and promoting its advanced therapeutic discovery technologies.
Read more →-OABI
Aug 17, 2026▲ +13%on this news· ran to +27% by day 3
OmniAb Raises 2026 Financial Guidance
OmniAb, Inc. has increased its financial guidance for 2026 due to successful technology licensing activities. This update reflects a stronger cash outlook for the company. CEO Matt Foehr highlighted the positive impact of recent business developments on their financial projections.
Read more →-OABI
Aug 17, 2026▲ +13%on this news· ran to +27% by day 3shared move
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb, Inc. has announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program. This partnership aims to leverage OmniAb's technology platform and expertise in ion channel discovery and screening. The agreement signifies a strategic move to enhance therapeutic development in this area.
Read more →-OABI
Aug 6, 2026▲ +37.5%on this news· ran to +53% by day 3
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. has reported its financial results for Q2 2026, showcasing a strong performance with increased revenue and an optimistic cash outlook for the year. The company highlighted ongoing progress in its operating and partner programs, reflecting positive business momentum. This update suggests a favorable trajectory for OmniAb as it advances its discovery research technology.
Read more →-OABI
Jul 16, 2026OmniAb to Report Second Quarter 2026 Financial Results on August 6
OmniAb, Inc. has announced that it will report its financial results for the second quarter of 2026 on August 6. The report will cover the three and six months ending June 30, 2026, and will be followed by a conference call at 4:30 p.m. Eastern time. This event reflects the company's commitment to keeping investors informed.
Read more →-OABI
Jul 13, 2026▼ -7.9%on this newsshared move
OmniAb Names Amechi Nwachuku Chief Operating Officer
OmniAb, Inc. has appointed Amechi Nwachuku as the new Chief Operating Officer. This newly-created position aims to enhance the strategy and operations of the company's proprietary technology, xPloration®. Nwachuku's appointment is expected to drive commercial success and innovation within the organization.
Read more →-OABI
May 7, 2026OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb has reported its financial results for the first quarter of 2026, along with key business highlights. The article provides insights into the company's performance and strategic initiatives during this period. However, specific details regarding financial metrics and business developments are not disclosed in the provided text.
Read more →-OABI
Apr 24, 2026▼ -6.4%on this news
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) will participate in three upcoming investor conferences. The events include a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, one-on-one meetings at the Benchmark 6th Annual Healthcare House Call Virtual Investor Conference on May 28, and a corporate overview at the Jefferies Global Healthcare Conference from June 2-4. These engagements highlight the company's commitment to investor relations.
Read more →-OABI
Apr 21, 2026OmniAb to Report First Quarter 2026 Financial Results on May 7
OmniAb, Inc. will announce its financial results for Q1 2026 on May 7, 2026, after market close. A conference call will follow at 4:30 p.m. Eastern time to discuss these results and provide business updates. The company is known for its advanced discovery technology in the biopharma sector.
Read more →-OABI
Mar 5, 2026▲ +10.5%on this news
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for Q4 and the full year of 2025, showing a decline in revenue and an increase in net loss compared to 2024. The company highlighted its expanding partner base and the launch of its new technology, OmniUltra™, while also providing financial guidance for 2026. Despite the challenges, OmniAb remains optimistic about its future growth prospects.
Read more →-OABI
Nov 4, 2025OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for Q3 and the first nine months of 2025, revealing a decline in revenue but an increase in the number of new programs and partnerships. The company plans to launch its OmniUltra technology in December 2025, which could unlock further business opportunities. Despite a consistent net loss compared to the previous year, OmniAb strengthened its balance sheet through a private placement in August. As of September 30, 2025, the company's cash and equivalents stood at $59.5 million, with expectations for revenue in 2025 estimated between $18 million and $22 million.
Read more →-OABI
Aug 25, 2025▼ -11.9%on this news
OmniAb Announces $30 Million Private Placement
OmniAb, Inc. has announced a definitive securities purchase agreement to raise approximately $30 million through a private placement of common stock. The company will issue 21,254,106 shares at a price of $1.40 per share, with officer and director participation priced at $1.85 per share. The net proceeds are intended for general corporate purposes, and the closing is expected to occur on August 26, 2025, pending customary closing conditions. Leerink Partners is acting as the sole placement agent for this financing.
Read more →-OABI
Aug 6, 2025▼ -5.4%on this news
OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for Q2 2025, highlighting the addition of six new license agreements and achieving 100 active partners. However, revenue fell to $3.9 million in Q2 2025, down from $7.6 million in Q2 2024, contributing to a net loss of $15.9 million. The company's recent initiatives include the launch of the xPloration Partner Access Program and a strong focus on innovation amidst operational adjustments.
Read more →-OABI
May 8, 2025OmniAb Reports First Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for Q1 2025, showing a revenue increase to $4.2 million. The company has initiated several new partnerships and programs aimed at advancing its technology. Despite a continued net loss of $18.2 million, OmniAb affirmed its 2025 revenue guidance and reduced its operating expense projections. The launch of the xPloration Partner Access Program is meant to enhance business opportunities and increase scalability of their technology platforms.
Read more →-OABI
Mar 18, 2025OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for the fourth quarter and full year of 2024, showcasing a notable increase in revenue for Q4 compared to the same time in 2023. The CEO highlighted substantial growth in active partners and clinical programs, alongside the launch of the OmniHub data interface. However, the total revenue for 2024 declined relative to 2023 due to previous milestone payments. The company also anticipates lower cash use and provided financial guidance for 2025, expecting revenue between $20 million and $25 million.
Read more →-OABI
Nov 12, 2024OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for the third quarter of 2024, showing a revenue decline to $4.2 million from $5.5 million in the same period last year. Despite this, the company noted growth in its technology platform and expanding partnership portfolio, reaching 86 active partners. The net loss for the quarter increased slightly to $16.4 million and the company expects operating expenses to remain lower than in 2023. Additionally, OmniAb is well-capitalized, having a cash balance projected between $50 million and $60 million by year-end 2024.
Read more →-OABI
Aug 8, 2024▲ +5.7%on this news
OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q2 2024, showcasing a revenue increase to $7.6 million compared to $6.9 million in Q2 2023. Despite a reduction in net losses, the overall revenue for the first half of 2024 decreased significantly compared to the previous year. The company also highlighted progress in partnerships and business development, suggesting a positive outlook for deal flow in the coming year. OmniAb's current cash position is expected to support operations adequately in the near future.
Read more →-OABI
May 9, 2024OmniAb Reports First Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q1 2024, highlighting a decrease in revenue to $3.8 million from $16.9 million in the same quarter of 2023. The increase in net loss to $19 million reflects ongoing expenses as the company continues to invest in research and development. Despite these challenges, OmniAb announced the addition of three new platform partners, bringing its total to 80. The company maintains expectations for continued growth in 2025, supported by its current cash reserve of $69 million.
Read more →About OmniAb, Inc. Common Stock
Headquarters5980 HORTON STREET, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE PLUS
Trade the next OABI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime